Trial Search Results
Home Away From Home - Quality of Life Surveys
Treatment for pediatric acute myeloid leukemia (AML) involves intensive chemotherapy regimens that result in periods of profound neutropenia leaving patients susceptible to severe infectious complications. Infectious complications are the leading cause of treatment related mortality among AML patients, but there are little clinical data to inform whether management of neutropenia post AML chemotherapy should occur in an outpatient or inpatient setting. Further, no studies have been conducted that assess the impact of neutropenia management strategy on the quality of life of pediatric patients with AML and their caregivers.
Stanford is currently not accepting patients for this trial.
Children's Hospital of Philadelphia
Collaborator: Dana-Farber Cancer Institute
1. Participants will be enrolled as patient-caregiver dyads. The patient must be:
- Less than 19 years of age at diagnosis.
- Patient is English or Spanish literate.
- Receiving chemotherapy for AML between June 1, 2016 and December 31, 2019.
2. Participants will be enrolled as patient-caregiver dyads. The caregiver must be:
- English or Spanish literate.
- The legal guardian of a patient receiving chemotherapy for AML between June 1,
2016 and December 31, 2019.
3. Parental/caregiver informed consent and, if appropriate, child assent.
1. Patients being treated for relapsed AML
2. Patients with Acute Promyelocytic Leukemia (APML)
3. Patients undergoing stem cell transplant (SCT)
4. Patients receiving reduced intensity frontline chemotherapy
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study